BioSpace News Archive

ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, announced that Company management will present at upcoming investor conferences

Arranta Bio announced the acquisition of Captozyme™, and with it the establishment of Arranta’s Center of Excellence for process and analytical development and early clinical supply for microbiome clients with the transfer of the Captozyme team and facilities in Gainesville, FL to Arranta.

PMC Group N.A., Inc. and Lanxess Organometallics GmbH are pleased to announce that the parties have reached an agreement whereby PMC’s European subsidiary will acquire the organotin specialties product line from Lanxess.

Cash, cash equivalents and financial assets of the Company amounted to €215.2 millioni

Bioservo has finished a successful long term trial with Ironhand® at Toyota Motor North America plants in Kentucky and West Virginia.

Enhancing the anti-tumor potential of CAR T cells for the treatment of solid tumors

Revenue includes sales of infectious disease, mosquito abatement products and AgBio primer design services

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended September 30, 2019.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Hunter Smith, Chief Financial Officer of Rhythm, will present a corporate overview at the Stifel 2019 Healthcare Conference on Wednesday, November 20, 2019 at 1:50 p.m. ET in New York, NY.

Reported Positive Topline Results from Pivotal Phase 3 URIROX-1 Trial of Reloxaliase in Enteric Hyperoxaluria (EH), with Statistically Significant Reduction in Urinary Oxalate (UOx) Compared to Placebo